|
58 |
기타암 |
Efficacy, safety, and feasibility of Apixaban for postoperative venous thromboembolism prophylaxis following open gynecologic cancer surgery at a comprehensive cancer center
|
2024-03-29 |
16 |
|
57 |
기타암 |
Correlation between second and first primary cancer: systematic review and meta-analysis of 9 million cancer patients
|
2024-03-29 |
6 |
|
56 |
난소암 |
Maintenance olaparib rechallenge in patients with platinum-sensitive relapsed ovarian cancer previously treated with a PARP inhibitor (OReO/ ENGOT-ov38): a phase IIIb trial
|
2024-03-29 |
11 |
|
55 |
난소암 |
Ofranergene Obadenovec (Ofra-Vec, VB-111) With Weekly Paclitaxel for Platinum-Resistant Ovarian Cancer: Randomized Controlled Phase III Trial (OVAL Study/GOG 3018)
|
2024-03-29 |
5 |
|
54 |
난소암 |
Clinical guidelines for ovarian cancer: the Korean Society of Gynecologic Oncology guidelines
|
2024-03-29 |
15 |
|
53 |
자궁경부암 |
Clinical practice guidelines for cervical cancer: the Korean Society of Gynecologic Oncology guidelines
|
2024-03-29 |
18 |
|
52 |
자궁경부암 |
Simple versus Radical Hysterectomy in Women with Low-Risk Cervical Cancer
|
2024-03-29 |
8 |
|
51 |
자궁경부암 |
Pembrolizumab or Placebo Plus Chemotherapy With or Without Bevacizumab for Persistent, Recurrent, or Metastatic Cervical Cancer
|
2024-03-29 |
5 |
|
50 |
자궁경부암 |
Neoadjuvant chemotherapy plus camrelizumab for locally advanced cervical cancer (NACI study): a multicentre, singlearm, phase 2 trial
|
2024-03-29 |
3 |
|
49 |
자궁경부암 |
Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial
|
2024-03-29 |
4 |
